In Vitro Diagnostics Market Research Reports & Industry Analysis
In Vitro Diagnostics Industry Research & Market Reports
-
Direct-to-Consumer (DTC) Genetic Testing
... 2030, growing at a CAGR of 14.0% over the analysis period 2024-2030. Ancestry & Relationship Testing, one of the segments analyzed in the report, is expected to record a 11.0% CAGR and reach US$1.3 Billion ... Read More
-
Hemoglobin A1C (HbA1C) Testing
... 2030, growing at a CAGR of 8.1% over the analysis period 2024-2030. Ion-Exchange High Performance Liquid Chromatography (HPLC) Technology, one of the segments analyzed in the report, is expected to record a 8.6% CAGR and ... Read More
-
Tuberculosis Testing
... CAGR of 4.9% over the analysis period 2024-2030. Culture-Based Tests, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$714.5 Million by the end of the analysis ... Read More
-
Artificial Intelligence (AI) in Medical Diagnostics
... reach US$4.4 Billion by 2030, growing at a CAGR of 22.2% over the analysis period 2024-2030. AI Software, one of the segments analyzed in the report, is expected to record a 24.0% CAGR and reach ... Read More
-
Predictive Genetic Testing and Consumer Genomics
... reach US$20.7 Billion by 2030, growing at a CAGR of 14.4% over the analysis period 2024-2030. Predictive Testing, one of the segments analyzed in the report, is expected to record a 14.3% CAGR and reach ... Read More
-
Reporter Gene Assays
... at a CAGR of 6.5% over the analysis period 2024-2030. Luciferase Assays, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$4.6 Billion by the end of ... Read More
-
Blood Group Typing
... at a CAGR of 9.6% over the analysis period 2024-2030. Blood Group Typing Consumables, one of the segments analyzed in the report, is expected to record a 9.9% CAGR and reach US$2.8 Billion by the ... Read More
-
Clinical Risk Grouping Solutions
... 2030, growing at a CAGR of 13.8% over the analysis period 2024-2030. Scorecard & Visualization Tools, one of the segments analyzed in the report, is expected to record a 15.1% CAGR and reach US$1.1 Billion ... Read More
-
Glucose Biosensors
... CAGR of 2.1% over the analysis period 2024-2030. Hospitals End-Use, one of the segments analyzed in the report, is expected to record a 1.8% CAGR and reach US$1.5 Billion by the end of the analysis ... Read More
-
Hepatitis Therapeutics
... CAGR of 3.7% over the analysis period 2024-2030. Hepatitis C Therapeutics, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$17.8 Billion by the end of the ... Read More
-
Liver Cancer Diagnostics
... at a CAGR of 7.4% over the analysis period 2024-2030. Laboratory Tests, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$9.8 Billion by the end of ... Read More
-
Oncology Based In-Vivo CRO
... 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Solid Tumors Indication, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$1.2 Billion by ... Read More
-
Automated and Rapid Microbiological Tests
... Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2024-2030. GC/CRT (Clinical) Application, one of the segments analyzed in the report, is expected to record a 8.0% CAGR and reach US$1.3 ... Read More
-
Cancer / Tumor Profiling
... 2030, growing at a CAGR of 9.9% over the analysis period 2024-2030. Immunoassays Technology, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$6.7 Billion by the ... Read More
-
Tissue Diagnostics
... CAGR of 6.6% over the analysis period 2024-2030. Tissue Diagnostics Consumables, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$8.4 Billion by the end of the ... Read More
-
Pathology Instruments
... CAGR of 5.6% over the analysis period 2024-2030. Molecular Diagnostics Technology, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$1.7 Billion by the end of the ... Read More
-
Clinical Chemistry Analyzers
... at a CAGR of 4.9% over the analysis period 2024-2030. Clinical Chemistry Analyzer Reagents, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$12.5 Billion by the ... Read More
-
Automated Blood Tube Labelers and Specimen Transport Boxes
... 2024, is expected to reach US$518.8 Million by 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. Hospitals End-Use, one of the segments analyzed in the report, is expected to record a ... Read More
-
Heparin
... 2.8% over the analysis period 2024-2030. Low Molecular Weight Heparin (LMWH), one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$5.9 Billion by the end of the ... Read More
-
Hemoglobin Testing
... CAGR of 5.6% over the analysis period 2024-2030. Hemoglobin Testing Reagents & Consumables, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$3.0 Billion by the end ... Read More
-
High-Density Multiplexed Diagnostic Assays
... 2030, growing at a CAGR of 14.7% over the analysis period 2024-2030. Diagnostic Laboratories End-Use, one of the segments analyzed in the report, is expected to record a 15.1% CAGR and reach US$1.8 Billion by ... Read More
-
Histology and Cytology
... at a CAGR of 14.4% over the analysis period 2024-2030. Cytology, one of the segments analyzed in the report, is expected to record a 15.3% CAGR and reach US$50.6 Billion by the end of the ... Read More
-
Industrial Microbiology
... CAGR of 4.6% over the analysis period 2024-2030. Pharmaceuticals End-Use, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$11.6 Billion by the end of the analysis ... Read More
-
Laboratory Automated Incubators
... at a CAGR of 4.0% over the analysis period 2024-2030. Pharma & Biotech Companies End-Use, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$399.4 Million by ... Read More
-
Leukapheresis
... 7.0% over the analysis period 2024-2030. Leukapheresis Devices, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$122.6 Million by the end of the analysis period. Growth ... Read More
Research Assistance
